Amgen to Host Summary Webcast of Kyprolis® (carfilzomib) for Injection Data Presented at The European Society for Medical Oncology (ESMO) 2014 Congress

Thu, 09/25/2014 -- Science News Desk

Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will host a summary webcast of Kyprolis® (carfilzomib) for Injection data presented at the European Society for Medical Oncology (ESMO) 2014 Congress on Monday, Sept. 29, 2014, at 1 p.m. PT. Pablo Cagnoni, M.D., president of Onyx Pharmaceuticals, Inc., along with clinical investigators, will participate in the call. In addition, they will discuss a summary of feedback received from key opinion leaders and the steps Amgen is taking to develop Kyprolis across all lines of therapy to address unmet needs in patients with multiple myeloma.

Live audio of the investor call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website,, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.




Disclaimer: The information provided on Science News is not intended to be a medical advice. The information on this website is also not intended to be used for diagnosis or treatment. The material provided on this site is of general informational purpose only. You may consult your physician or other qualified health provider for medical advice, diagnosis or treatment.  The inventions, discoveries, devices or products mentioned on Science News may be in planning or experimental stages and may not have approval from regulatory agencies for human or animal use.